Over the next five years, we forecast operating profit margin to expand approximately 500 basis points, from 12.6% in 2023 to high double digits, which we think can be achieved with a combination of ...

BASKING RIDGE, N.J., November 13, 2024--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and ...

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November ...

Tecsys Inc. , a global provider of supply chain management solutions, has been named a "Leader" in the 2024 Nucleus Research WMS Technology Value Matrix. According to the technology research and ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients ...

Qu – which, according to Parsa, is the fruit of a collaboration between a global team of experienced AI scientists, ...